Bone Biologics Corporation has received a letter from Nasdaq confirming that it complies with the requirements for continuous listing on The Nasdaq Capital Market. However, it'll be monitored till June 27, 2024 and if it fails to meet requirements during the monitoring period, it won't get the chance to present a compliance plan nor additional time will be granted.